CKX Stock Overview
Provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cryoport, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.25 |
| 52 Week High | US$18.00 |
| 52 Week Low | US$4.92 |
| Beta | 1.62 |
| 1 Month Change | 10.69% |
| 3 Month Change | 2.11% |
| 1 Year Change | -48.94% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| CKX | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -1.4% | 0.1% | 0.3% |
| 1Y | -48.9% | -5.3% | 6.9% |
Return vs Industry: CKX underperformed the German Life Sciences industry which returned -4.5% over the past year.
Return vs Market: CKX underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| CKX volatility | |
|---|---|
| CKX Average Weekly Movement | 11.2% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CKX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CKX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,100 | Jerry Shelton | www.cryoportinc.com |
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services.
Cryoport, Inc. Fundamentals Summary
| CKX fundamental statistics | |
|---|---|
| Market cap | €370.68m |
| Earnings (TTM) | -€160.04m |
| Revenue (TTM) | €217.39m |
1.7x
P/S Ratio-2.3x
P/E RatioIs CKX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CKX income statement (TTM) | |
|---|---|
| Revenue | US$226.11m |
| Cost of Revenue | US$130.50m |
| Gross Profit | US$95.61m |
| Other Expenses | US$262.08m |
| Earnings | -US$166.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.37 |
| Gross Margin | 42.28% |
| Net Profit Margin | -73.62% |
| Debt/Equity Ratio | 47.6% |
How did CKX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 17:44 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cryoport, Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashok Kumar | Aegis Capital Corporation |
| Yuan Zhi | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |